{"content":"<li class=\"n-box-item date-title\" data-end=\"1512709199\" data-start=\"1512622800\" data-txt=\"Monday, December 23, 2019\">Thursday, December  7, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3317139\" data-ts=\"1512693834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317139-alexionplus-2_6-on-report-elliott-taken-activist-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion +2.6% on report Elliott has taken activist stake</a></h4><ul>   <li>Activist Elliott Management has <a href=\"https://www.nytimes.com/2017/12/07/business/dealbook/elliott-alexion-activist-investor.html\" target=\"_blank\">turned its sights on Alexion Pharmaceuticals</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>), taking a stake in the biopharma and pushing for ways to lift its share price, <i>The New York Times</i> reports.</li>    <li>That means a proxy fight could be ahead if there's inaction, sources told the paper.</li>    <li>Alexion shares are <font color='green'>up 2.6%</font> after hours.</li>    <li>Alexion, worth just shy of $24B at today's close, has been working to recover from problems under previous management. Much of the senior team has been replaced since Ludwig Hantson took over in March, and the company this fall announced plans to lay of 20% of its workforce and invest in new treatments.</li>    <li>The deadline for nominating directors comes at the end of the month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317139\" data-linked=\"Alexion +2.6% on report Elliott has taken activist stake\" data-tweet=\"$ALXN - Alexion +2.6% on report Elliott has taken activist stake https://seekingalpha.com/news/3317139-alexionplus-2_6-on-report-elliott-taken-activist-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3317139-alexionplus-2_6-on-report-elliott-taken-activist-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317137\" data-ts=\"1512692137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNOV\" target=\"_blank\">MNOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317137-medicinovaplus-52-on-positive-trial-results-for-mnminus-166-in-als\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediciNova +52% on positive trial results for MN-166 in ALS</a></h4><ul>     <li>MediciNova (NASDAQ:<a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a>) <font color='green'>+52.7%</font> after-hours on news it <a href=\"https://seekingalpha.com/pr/17021953-medicinova-announces-positive-top-line-results-clinical-trial-mnminus-166-ibudilast-als\" target=\"_blank\">received positive top-line results</a> from its clinical trial of MN-166 (ibudilast) drug in amyotrophic lateral sclerosis.</li>     <li>MNOV says the trial achieved the primary endpoint of safety and tolerability, and demonstrated efficacy trends in favor of MN-166.</li>     <li>MNOV says it is attempting to develop MN-166 for progressive multiple sclerosis and other neurological conditions such as ALS.</li>     <li>The drug has been marketed in Japan and South Korea to treat post-stroke complications and bronchial asthma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317137\" data-linked=\"MediciNova +52% on positive trial results for MN-166 in ALS\" data-tweet=\"$MNOV - MediciNova +52% on positive trial results for MN-166 in ALS https://seekingalpha.com/news/3317137-medicinovaplus-52-on-positive-trial-results-for-mnminus-166-in-als?source=tweet\" data-url=\"https://seekingalpha.com/news/3317137-medicinovaplus-52-on-positive-trial-results-for-mnminus-166-in-als\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317136\" data-ts=\"1512691038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DTEA\" target=\"_blank\">DTEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317136-davids-tea-evaluating-options-including-potential-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">David&#39;s Tea evaluating options, including potential sale</a></h4><ul>     <li>David's Tea (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a>)&nbsp;<font color='green'>+2.5%</font> after-hours, as the Canadian tea seller says it is exploring strategic alternatives including a <a href=\"http://business.financialpost.com/news/retail-marketing/davidstea-evaluating-options-including-sale-just-two-years-after-going-public\" target=\"_blank\">potential sale of the company</a>, just two years after going public.</li>     <li>The company says it is considering include selling assets and seeking joint venture partners as well as putting itself up for sale.</li>     <li>DTEA made its announcement while reporting weaker than expected <a href=\"https://seekingalpha.com/news/3317061-davids-tea-reports-q3-results\" target=\"_blank\">Q3 earnings</a>, as same-store sales fell 6.8% Y/Y, reflecting challenges in accessories and kits that &ldquo;did not excite the customer.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317136\" data-linked=\"David&#39;s Tea evaluating options, including potential sale\" data-tweet=\"$DTEA - David&#39;s Tea evaluating options, including potential sale https://seekingalpha.com/news/3317136-davids-tea-evaluating-options-including-potential-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3317136-davids-tea-evaluating-options-including-potential-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317135\" data-ts=\"1512689952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317135-smith-wesson-parent-american-outdoorminus-14-after-cutting-eps-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smith &amp; Wesson parent American Outdoor -14% after cutting EPS outlook</a></h4><ul>     <li>American Outdoor Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>) <font color='red'>-14.4%</font> after-hours in the wake of sharp Y/Y declines in <a href=\"https://seekingalpha.com/news/3317063-american-outdoor-brands-beats-0_04-beats-revenue\" target=\"_blank\">FQ2 earnings</a> and revenues, as the Smith &amp;&nbsp;Wesson parent company also <a href=\"https://www.marketwatch.com/story/gun-maker-american-outdoor-slashes-earnings-forecast-amid-challenging-market-conditions-2017-12-07\" target=\"_blank\">warns of continued difficulties</a>.</li>     <li>Adjusted earnings for the quarter came in at a better than expected $0.11/share but still were far short of the $0.68 in the year-ago period, and sales of $148.4M were more than a third lower than last year's $233.5M.</li>     <li>AOBC sees FQ3 adjusted EPS of $0.07-$0.10 on revenues of $170M-$180M, and full-year EPS of $0.57-$0.67 on sales of $650M-$675M, well below analyst expectations of $0.41 EPS on sales of $209M for the current quarter and $1.09 EPS on $711M in sales for the full year; the company previously had forecast full-year EPS of $1.04-$1.24 on sales of $700M-$740M.</li>     <li>On Q2, CEO&nbsp;James Debney says \"Lower shipments in our firearms business reflected a significant reduction in wholesaler and retailer orders vs. the prior year,\" adding that strong firearm sales in the year-ago quarter were \"driven by personal safety concerns and pre-election fears of increased firearm legislation.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317135\" data-linked=\"Smith &amp; Wesson parent American Outdoor -14% after cutting EPS outlook\" data-tweet=\"$AOBC - Smith &amp; Wesson parent American Outdoor -14% after cutting EPS outlook https://seekingalpha.com/news/3317135-smith-wesson-parent-american-outdoorminus-14-after-cutting-eps-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3317135-smith-wesson-parent-american-outdoorminus-14-after-cutting-eps-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317132\" data-ts=\"1512687754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TELL\" target=\"_blank\">TELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317132-tellurian-to-launch-8m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tellurian to launch 8M-share offering</a></h4><ul>     <li>Tellurian (NASDAQ:<a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a>) <font color='red'>-11.7%</font>&nbsp;after-hours as it announces a <a href=\"https://seekingalpha.com/pr/17021849-tellurian-announces-public-offering-common-stock\" target=\"_blank\">public offering</a> of 8M common shares, with an underwriters option to purchase up to an additional 1.2M shares.</li>     <li>TELL says it plans to use the proceeds from the offering for detailed engineering of a liquefied natural gas terminal facility and an associated pipeline in Louisiana, plus general corporate purposes and working capital.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317132\" data-linked=\"Tellurian to launch 8M-share offering\" data-tweet=\"$TELL - Tellurian to launch 8M-share offering https://seekingalpha.com/news/3317132-tellurian-to-launch-8m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317132-tellurian-to-launch-8m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317126\" data-ts=\"1512686142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317126-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color='green'>+5.5%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/OCSL' title='Oaktree Specialty Lending Corporation'>OCSL</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+4.0%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-13.6%</font>. <a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/COO' title='The Cooper Companies Inc.'>COO</a>&nbsp;<font color='red'>-2.2%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT'>XENT</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/NVRO' title='Nevro'>NVRO</a> <font color='red'>-1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317126\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CLDR $DCIX $OCSL - After Hours Gainers / Losers https://seekingalpha.com/news/3317126-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317126-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317125\" data-ts=\"1512686107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEA\" target=\"_blank\">DEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317125-easterly-reit-cutera-bounce-on-additions-to-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Easterly REIT, Cutera bounce on additions to SmallCap 600</a></h4><ul>   <li>Government-focused REIT Easterly Government Properties (NYSE:<a href='https://seekingalpha.com/symbol/DEA' title='Easterly Government Properties'>DEA</a>) is <font color='green'>up 4.8%</font> after hours on word it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/627755_cuteastofpharmerica.pdf?force_download=true\" target=\"_blank\">moving into the S&amp;P SmallCap 600</a>.</li>    <li>The company's replacing PharMerica (NYSE:<a href='https://seekingalpha.com/symbol/PMC' title='PharMerica Corporation'>PMC</a>) in that index after the latter's acquisition by KKR closed today. The move's effective prior to Tuesday's open.</li>    <li>Also joining the 600 is laser maker Cutera (NASDAQ:<a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a>), <font color='green'>up 2%</font> after hours. Effective prior to the open on Friday, Dec. 15, Cutera will replace Tesco (NASDAQ:<a href='https://seekingalpha.com/symbol/TESO' title='Tesco Corporation'>TESO</a>), which is being acquired by Nabors Industries.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317125\" data-linked=\"Easterly REIT, Cutera bounce on additions to SmallCap 600\" data-tweet=\"$DEA $DEA $PMC - Easterly REIT, Cutera bounce on additions to SmallCap 600 https://seekingalpha.com/news/3317125-easterly-reit-cutera-bounce-on-additions-to-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3317125-easterly-reit-cutera-bounce-on-additions-to-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317114\" data-ts=\"1512683947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLED\" target=\"_blank\">OLED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317114-universal-display-announces-oled-agreement-boe-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Universal Display announces OLED agreement with BOE Technology</a></h4><ul><li>        Universal Display Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a>) <a href=\"https://seekingalpha.com/filing/3791934\" target=\"_blank\">enters</a> into a long-term, multi-year agreement with BOE Technology Group for supplying phosphorescent OLED materials to use in BOE&rsquo;s products.</li><li>               Financial terms not disclosed.&nbsp;</li><li>               Universal Display shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;aftermarket. &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3308065-universal-display-q3-beats-upside-fy17-guidance\" target=\"_blank\">Universal Display up after Q3 beats, upside FY17 guidance</a> (Nov. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317114\" data-linked=\"Universal Display announces OLED agreement with BOE Technology\" data-tweet=\"$OLED - Universal Display announces OLED agreement with BOE Technology https://seekingalpha.com/news/3317114-universal-display-announces-oled-agreement-boe-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3317114-universal-display-announces-oled-agreement-boe-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317089\" data-ts=\"1512682250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDR\" target=\"_blank\">CLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317089-clouderaplus-4_8-after-q3-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloudera +4.8% after Q3 beats, upside guidance</a></h4><ul><li>        Cloudera (NYSE:<a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a>) shares are&nbsp;<font color='green'>up 4.8%</font>&nbsp;after reporting Q3 results that beat revenue and EPS estimates. Q4 guidance has revenue from $97M to $99M (consensus: $97.31M) and EPS from -$0.24 to -$0.22 (consensus: -$0.26). &nbsp;</li><li>        FY18 guidance: revenue, $361M to $363M (consensus: $358.67M); EPS, -$0.84 to -$0.82 (consensus: -$0.93).</li><li>               Key metrics: Subscription revenue, $78.1M (+48% Y/Y); subscription gross margin, 86%; operating cash flow, -$2.4M; operating expenses, $118M; cash and equivalents, $484M; Global 8000 customer net add, 23.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17021790-cloudera-reports-third-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317066-cloudera-beats-0_07-beats-revenue\" target=\"_blank\">Cloudera beats by $0.07, beats on revenue</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317089\" data-linked=\"Cloudera +4.8% after Q3 beats, upside guidance\" data-tweet=\"$CLDR - Cloudera +4.8% after Q3 beats, upside guidance https://seekingalpha.com/news/3317089-clouderaplus-4_8-after-q3-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3317089-clouderaplus-4_8-after-q3-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317086\" data-ts=\"1512682001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENZ\" target=\"_blank\">ENZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317086-enzo-biochem-fiscal-q1-top-line-up-5-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enzo Biochem fiscal Q1 top line up 5%; shares down 2% after hours</a></h4><ul><li>Enzo Biochem (NYSE:<a href='https://seekingalpha.com/symbol/ENZ' title='Enzo Biochem, Inc.'>ENZ</a>) fiscal <a href=\"https://seekingalpha.com/pr/17021804-enzo-biochem-reports-improved-first-quarter-results\" target=\"_blank\">Q1 results</a> ($M): Revenues: 27.7 (+5.3%); Lab Services: 20.3 (+9.1%).</li><li>Net Loss: (0.6) (+56.6%); Loss/share: (0.01) (+66.7%).</li><li>NY State Health Department approved final three molecular diagnostic tests in 13-analyte women's health panel.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317086\" data-linked=\"Enzo Biochem fiscal Q1 top line up 5%; shares down 2% after hours\" data-tweet=\"$ENZ - Enzo Biochem fiscal Q1 top line up 5%; shares down 2% after hours https://seekingalpha.com/news/3317086-enzo-biochem-fiscal-q1-top-line-up-5-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3317086-enzo-biochem-fiscal-q1-top-line-up-5-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317083\" data-ts=\"1512681714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317083-finisar-gains-q2-revenue-decline-smaller-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finisar gains with Q2 revenue decline smaller than expected</a></h4><ul>   <li>Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) is <font color='green'>up 3.1%</font> after hours on heavy postmarket volume after <a href=\"https://seekingalpha.com/news/3317058-finisar-misses-0_07-beats-revenue\" target=\"_blank\">fiscal Q2 earnings</a> where profits fell short, and revenues declined but beat Street consensus.</li>    <li>The company saw strong demand for its 100G transceivers for data centers, says CEO Jerry Rawls, but revenues fell 2.8% sequentially (and more than 10% Y/Y) \"primarily due to lower revenues from our Chinese OEM customers.\"</li>    <li>Sales of datacom products fell by $1.7M (down 0.7% Q/Q) amid lower demand for 10G-and-below transceivers, 40G QSFP transceivers, and 100G CFP Ethernet transceivers.</li>    <li>Telecom products, meanwhile, declined 9.5% Q/Q ($7.9M) on lower Chinese OEM demand.</li>    <li>Margins declined sequentially across the board: Non-GAAP gross margin fell to 30.3% from 34.9%, and operating margin dropped to 7.8% from 13.5%.</li>    <li>For Q3, it's guiding to revenues of $325M-$345M (vs. consensus for $344M), gross margin (non-GAAP) of 30-31%, operating margin of 7.5-8.5%, and EPS of $0.21-$0.27 (below $0.33 consensus).</li>    <li><a href=\"http://investor.finisar.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17021774-finisar-announces-second-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3317083\" data-linked=\"Finisar gains with Q2 revenue decline smaller than expected\" data-tweet=\"$FNSR - Finisar gains with Q2 revenue decline smaller than expected https://seekingalpha.com/news/3317083-finisar-gains-q2-revenue-decline-smaller-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3317083-finisar-gains-q2-revenue-decline-smaller-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317059\" data-ts=\"1512680673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENC\" target=\"_blank\">FENC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317059-fennec-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fennec readies equity offering</a></h4><ul><li>Fennec Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals, Inc.'>FENC</a>) <a href=\"https://seekingalpha.com/pr/17021773-fennec-announces-proposed-public-offering-common-shares\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317059\" data-linked=\"Fennec readies equity offering\" data-tweet=\"$FENC - Fennec readies equity offering https://seekingalpha.com/news/3317059-fennec-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317059-fennec-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317053\" data-ts=\"1512680280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317053-petrobras-promises-to-revise-lpg-pricing-policy-after-spike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras promises to revise LPG pricing policy after spike</a></h4><ul>     <li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='red'>-2.8%</font>) says it will <a href=\"https://www.reuters.com/article/petrobras-lpg/brazils-petrobras-to-revise-pricing-policy-for-lpg-after-price-spike-idUSL1N1O717W\" target=\"_blank\">review its pricing policy for liquefied petroleum gas</a>, following a 70% price spike since June for the fuel which is widely used by Brazilians for cooking.</li>     <li>The state-controlled company says it will review the policy, which currently follows international prices, since &ldquo;reference markets in Europe have been highly volatile because of winter.&rdquo;</li>     <li>PBR says the 8.9% price rise announced this week was the last under the current scheme.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317053\" data-linked=\"Petrobras promises to revise LPG pricing policy after spike\" data-tweet=\"$PBR - Petrobras promises to revise LPG pricing policy after spike https://seekingalpha.com/news/3317053-petrobras-promises-to-revise-lpg-pricing-policy-after-spike?source=tweet\" data-url=\"https://seekingalpha.com/news/3317053-petrobras-promises-to-revise-lpg-pricing-policy-after-spike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317048\" data-ts=\"1512678810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCLP\" target=\"_blank\">HCLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317048-hi-crush-partners-started-buy-rating-b-riley-fbr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hi-Crush Partners started with Buy rating at B. Riley FBR</a></h4><ul>     <li>Hi-Crush Partners (<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+1.2%</font>) is higher after B. Riley FBR initiates coverage of the stock with a <a href=\"https://www.streetinsider.com/Analyst+Comments/B.RileyFBR+Starts+Hi-Crush+Partners+LP+%28HCLP%29+at+Buy/13577007.html\" target=\"_blank\">Buy rating</a> and a $16 price target.</li>     <li>HCLP is \"well positioned to grow distributions over the coming years due to high-return growth projects in both sand mining and logistics, complementing what we believe is already an attractive combination of low-cost mining and infrastructure assets,\" the firm writes.</li>     <li>B. Riley FBR also starts U.S. Silica (<a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='green'>+2%</font>) at Buy, and  Emerge Energy Services (<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-5.8%</font>) and Fairmount Santrol (<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+3.4%</font>) with Neutral ratings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317048\" data-linked=\"Hi-Crush Partners started with Buy rating at B. Riley FBR\" data-tweet=\"$HCLP $HCR $SLCA - Hi-Crush Partners started with Buy rating at B. Riley FBR https://seekingalpha.com/news/3317048-hi-crush-partners-started-buy-rating-b-riley-fbr?source=tweet\" data-url=\"https://seekingalpha.com/news/3317048-hi-crush-partners-started-buy-rating-b-riley-fbr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317044\" data-ts=\"1512678224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317044-qualcomm-and-baidu-announce-ai-iot-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm and Baidu announce AI, IoT collaboration</a></h4><ul><li>        Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) and Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) <a href=\"https://www.qualcomm.com/news/releases/2017/12/07/qualcomm-and-baidu-announce-strategic-collaboration-support-optimized\" target=\"_blank\">announce</a> a strategic collaboration to optimize Baidu&rsquo;s DuerOS for Qualcomm&rsquo;s Snapdragon Mobile Platform including the newly announced Snapdragon 845.</li><li>                  DuerOS is a conversational artificial intelligence system for smartphones. Combined with Qualcomm&rsquo;s Aqstic hardware and software, the companies can support a complete AI voice and smart assistant solution for smartphones and IoT devices.    </li><li>               Baidu shares are&nbsp;<font color='green'>up 1.5%</font>.&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316740-qualcomm-reveals-snapdragon-845-detail\" target=\"_blank\">Qualcomm reveals Snapdragon 845 detail</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317044\" data-linked=\"Qualcomm and Baidu announce AI, IoT collaboration\" data-tweet=\"$QCOM $QCOM $BIDU - Qualcomm and Baidu announce AI, IoT collaboration https://seekingalpha.com/news/3317044-qualcomm-and-baidu-announce-ai-iot-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3317044-qualcomm-and-baidu-announce-ai-iot-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317042\" data-ts=\"1512677919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317042-national-beverage-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage beats by $0.04, beats on revenue</a></h4><ul><li>National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>): Q2 EPS of $0.72 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $244.12M (+20.1% Y/Y) <font color='green'>beats by $5.09M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/17021478-national-beverage-corp-growth-accelerates-track-billion-dollar-revenues-504-million-first-6'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317042\" data-linked=\"National Beverage beats by $0.04, beats on revenue\" data-tweet=\"$FIZZ - National Beverage beats by $0.04, beats on revenue https://seekingalpha.com/news/3317042-national-beverage-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3317042-national-beverage-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317040\" data-ts=\"1512677721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCMP\" target=\"_blank\">SCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317040-sucampo-mulling-acquisition-offer-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sucampo mulling acquisition offer; shares up 5%</a></h4><ul><li>Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2017-12-07/sucampo-is-said-to-weigh-sale-after-receiving-takeover-interest\" target=\"_blank\">reports </a>that Sucampo Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='green'>+4.7%</font>) has received takeover interest. Management is apparently considering its options which may include making acquisitions itself.</li><li>Shares have rallied almost&nbsp;<font color='green'>50%</font>&nbsp;since late November.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317040\" data-linked=\"Sucampo mulling acquisition offer; shares up 5%\" data-tweet=\"$SCMP - Sucampo mulling acquisition offer; shares up 5% https://seekingalpha.com/news/3317040-sucampo-mulling-acquisition-offer-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3317040-sucampo-mulling-acquisition-offer-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317033\" data-ts=\"1512676516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317033-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ICAD' title='iCAD, Inc.'>ICAD</a> <font color='green'>+10%</font>.</li>     <li><strong>Losers</strong>: <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MEI' title='Methode Electronics, Inc.'>MEI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a> <font color='red'>-9%</font>.<strong> </strong></li><strong> &nbsp;</strong>     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3317033\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$SEAC $DPW $EGAN - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3317033-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317033-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317023\" data-ts=\"1512673261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317023-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317023\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$VHI $YTEN $TROX - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3317023-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317023-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317020\" data-ts=\"1512672350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMCX\" target=\"_blank\">AMCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317020-positive-talk-from-cooperman-on-amc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Positive talk from Cooperman on AMC</a></h4><ul>     <li>Leon Cooperman pitched AMC Networks (<a href='https://seekingalpha.com/symbol/AMCX' title='AMC Networks Inc.'>AMCX</a> <font color='green'>+1.5%</font>) as a long pick during an interview with <a href=\"https://www.cnbc.com/video/\" target=\"_blank\">CNBC</a>. He called shares undervalued at their current level.</li>     <li>Cooperman's Omega Advisors took a stake in AMC in Q1 and reported a 5.84% passive position as of November 3.</li><li>AMC trades on the low end of its 52-week range of $10.80 to $35.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317020\" data-linked=\"Positive talk from Cooperman on AMC\" data-tweet=\"$AMCX - Positive talk from Cooperman on AMC https://seekingalpha.com/news/3317020-positive-talk-from-cooperman-on-amc?source=tweet\" data-url=\"https://seekingalpha.com/news/3317020-positive-talk-from-cooperman-on-amc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317014\" data-ts=\"1512670635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPHI\" target=\"_blank\">IPHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317014-rosenblatt-downgrades-inphi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt downgrades Inphi</a></h4><ul><li>           Rosenblatt downgrades Inphi (NYSE:<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a>) from Neutral to Buy. </li><li>           Latest analyst recommendations (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=IPHI:NYQ\" target=\"_blank\">FT):</a> 5 Buy, 6 Outperform, and 2 Hold.  </li><li> Median price target: $46.&nbsp; </li><li> Inphi shares are&nbsp;<font color='red'>down 3.9%</font>. </li><li>Previously: <a href=\"https://seekingalpha.com/news/3306344-inphi-reports-q3-beats-line-guidance\" target=\"_blank\">Inphi reports Q3 beats, in-line guidance</a> (Oct. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317014\" data-linked=\"Rosenblatt downgrades Inphi\" data-tweet=\"$IPHI - Rosenblatt downgrades Inphi https://seekingalpha.com/news/3317014-rosenblatt-downgrades-inphi?source=tweet\" data-url=\"https://seekingalpha.com/news/3317014-rosenblatt-downgrades-inphi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317013\" data-ts=\"1512670381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCWX\" target=\"_blank\">SCWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317013-jpmorgan-downgrades-secureworks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan downgrades SecureWorks</a></h4><ul><li>        JPMorgan <a href=\"http://news.morningstar.com/all/market-watch/TDJNMW20171207422/secureworks-stock-sinks-after-jp-morgan-abandons-bullish-view.aspx\" target=\"_blank\">downgrades</a> SecureWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a>) from Neutral to Overweight and lowers the price target to $12 from $15.</li><li>        Analyst Sterling Auty notes that SecureWorks beat Q3 estimates but included downgrade guidance that Auty says could show caution after the departure of the CRO in October.</li><li>               Auty does call SecureWorks the &ldquo;best positioned&rdquo; among the managed security service providers. &nbsp;&nbsp;</li><li>               SecureWorks shares are&nbsp;<font color='red'>down 7.5%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316584-secureworks-reports-q3-beats-downside-guidance\" target=\"_blank\">SecureWorks reports Q3 beats, downside guidance</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317013\" data-linked=\"JPMorgan downgrades SecureWorks\" data-tweet=\"$SCWX - JPMorgan downgrades SecureWorks https://seekingalpha.com/news/3317013-jpmorgan-downgrades-secureworks?source=tweet\" data-url=\"https://seekingalpha.com/news/3317013-jpmorgan-downgrades-secureworks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317012\" data-ts=\"1512669945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVID\" target=\"_blank\">AVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317012-dougherty-co-downgrades-avid-tech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dougherty &amp; Co. downgrades Avid Tech</a></h4><ul><li>        Dougherty &amp; Company <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171207122813AVID\" target=\"_blank\">downgrades</a> Avid Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a>) from Neutral to Sell with a $4.50 price target.</li><li>               Firm says Avid has shown important progress over the last few quarters in terms of bookings and expense control, but the company doesn&rsquo;t see a path to sustainable top-line growth, better profitability, and material generation of FCF.&nbsp;</li><li>                  The firm sees more downside than not while Avid trades at 9x EV/18 EBITDA.&nbsp;    </li><li>               Avid shares are&nbsp;<font color='red'>down 9.4%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311130-avid-technology-plus-22_5-percent-mixed-q3-upside-guidance\" target=\"_blank\">Avid Technology +22.5% after mixed Q3, upside guidance</a> (Nov. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317012\" data-linked=\"Dougherty &amp; Co. downgrades Avid Tech\" data-tweet=\"$AVID - Dougherty &amp; Co. downgrades Avid Tech https://seekingalpha.com/news/3317012-dougherty-co-downgrades-avid-tech?source=tweet\" data-url=\"https://seekingalpha.com/news/3317012-dougherty-co-downgrades-avid-tech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317010\" data-ts=\"1512669771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEI\" target=\"_blank\">MEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317010-methode-electronicsminus-8_5-after-q2-results-and-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Methode Electronics -8.5% after Q2 results and mixed guidance</a></h4><ul><li>           Methode Electronics (NYSE:<a href='https://seekingalpha.com/symbol/MEI' title='Methode Electronics, Inc.'>MEI</a>) shares are&nbsp;<font color='red'>down 8.2%</font>&nbsp;after Q2 results beat revenue estimates and met on EPS and included mixed guidance. </li><li> FY18 guidance has revenue from $880M to $900M (consensus: $877.05M, was: $807M to $827M) and EPS from $2.43 to $2.63 (consensus: $2.59). </li><li> <a href=\"https://seekingalpha.com/pr/17020811-methode-electronics-inc-reports-fiscal-2018-second-quarter-sales-earnings\" target=\"_blank\">Press release</a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3316842-methode-electronics-eps-line-beats-revenue\" target=\"_blank\">Methode Electronics EPS in-line, beats on revenue</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317010\" data-linked=\"Methode Electronics -8.5% after Q2 results and mixed guidance\" data-tweet=\"$MEI - Methode Electronics -8.5% after Q2 results and mixed guidance https://seekingalpha.com/news/3317010-methode-electronicsminus-8_5-after-q2-results-and-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3317010-methode-electronicsminus-8_5-after-q2-results-and-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317004\" data-ts=\"1512668685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317004-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='green'>+75%</font>. <a href='https://seekingalpha.com/symbol/ENTL' title='Entellus Medical'>ENTL</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+16%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/NTN' title='NTN Buzztime, Inc'>NTN</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/AGX' title='Argan, Inc.'>AGX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CVO' title='Cenveo, Inc.'>CVO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ONS-OLD' title='Oncobiologics'>ONS-OLD</a> <font color='red'>-12%</font>.</li>      &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3317004\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SAGE $ENTL $GALT - Midday Gainers / Losers https://seekingalpha.com/news/3317004-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317004-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316998\" data-ts=\"1512666336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316998-vernit-systemsminus-8_9-despite-q3-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vernit Systems -8.9% despite Q3 beats, in-line guidance</a></h4><ul><li>        Verint Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a>) shares are&nbsp;<font color='red'>down 8.9%</font>&nbsp;despite Q3 results beat revenue and EPS estimates.</li><li>               FY18 guidance has revenue from $1.13B to $1.15B (consensus: $1.14B) and EPS at $2.75 (consensus: $2.76).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17020473-verint-reports-third-quarter-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316751-verint-systems-beats-0_08-beats-revenue\" target=\"_blank\">Verint Systems beats by $0.08, beats on revenue</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316998\" data-linked=\"Vernit Systems -8.9% despite Q3 beats, in-line guidance\" data-tweet=\"$VRNT - Vernit Systems -8.9% despite Q3 beats, in-line guidance https://seekingalpha.com/news/3316998-vernit-systemsminus-8_9-despite-q3-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316998-vernit-systemsminus-8_9-despite-q3-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316997\" data-ts=\"1512666166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316997-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HOFT' title='Hooker Furniture Corporation'>HOFT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc.'>BTN</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316997\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$HOME $GEF $VNCE - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3316997-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3316997-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316994\" data-ts=\"1512665488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKS\" target=\"_blank\">AKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316994-ak-steel-upgraded-j-p-morgan-on-expectations-of-higher-steel-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AK Steel upgraded at J.P. Morgan on expectations of higher steel prices</a></h4><ul>     <li>AK&nbsp;Steel (<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+5.3%</font>) is higher after J.P. Morgan <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/12/10884989/ak-steel-upgraded-on-expectations-of-higher-steel-price\" target=\"_blank\">upgrades</a> shares to Overweight from Neutral with a $7 price target, hiked from $6, saying the Department of Commerce's ruling against China redirecting steel to Vietnam will push steel prices higher in the U.S.</li>     <li>\"The retroactive nature of the duties will make importers of record in the U.S. more reluctant to buy \"cheap\" imports in the future and should support higher steel prices in the U.S.,\" JPM analyst Michael Gambardella writes.</li>     <li>Given the outlook for higher steep prices, JPM raises its 2018 EPS estimate to $1.00 from $0.83 and says earnings should increase sequentially throughout 2018 from a base of a $0.13/share loss in Q4 2017 due to higher maintenance and input costs, lower shipments and lower prices.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316994\" data-linked=\"AK Steel upgraded at J.P. Morgan on expectations of higher steel prices\" data-tweet=\"$AKS - AK Steel upgraded at J.P. Morgan on expectations of higher steel prices https://seekingalpha.com/news/3316994-ak-steel-upgraded-j-p-morgan-on-expectations-of-higher-steel-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3316994-ak-steel-upgraded-j-p-morgan-on-expectations-of-higher-steel-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316991\" data-ts=\"1512665228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316991-bitcoin-goes-parabolic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin goes (more) parabolic</a></h4><ul><li>Little more than one day ago, Bitcoin had never been higher than $13K. In a continuation of frenzied action, the price hit $19.5K a few minutes ago. That's according to Google Finance. Prices are varying widely and wildly across exchanges.</li><li>GF is showing a current price of $18,070.</li><li>Major U.S. exchange Coinbase has crashed again.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3316991\" data-linked=\"Bitcoin goes (more) parabolic\" data-tweet=\"$GBTC $GBTC $COIN - Bitcoin goes (more) parabolic https://seekingalpha.com/news/3316991-bitcoin-goes-parabolic?source=tweet\" data-url=\"https://seekingalpha.com/news/3316991-bitcoin-goes-parabolic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>339&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316990\" data-ts=\"1512665198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316990-oktaplus-2_4-after-q3-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta +2.4% after Q3 beats, upside guidance</a></h4><ul><li>        Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) shares are up 2.4% after Q3 results beat EPS and revenue estimates. Upside Q4 guidance has revenue from $70M to $71M (consensus: $67.86M) and EPS from -$0.18 to -$0.17 (consensus: -$0.20).</li><li>               FY18 guidance: revenue, $252M to $253M (consensus: $244.72M); EPS, -$0.87 to -$0.86 (consensus: -$0.96). &nbsp;&nbsp;&nbsp;</li><li><a href=\"https://seekingalpha.com/pr/17020455-okta-announces-record-third-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316754-okta-beats-0_05-beats-revenue\" target=\"_blank\">Okta beats by $0.05, beats on revenue</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316990\" data-linked=\"Okta +2.4% after Q3 beats, upside guidance\" data-tweet=\"$OKTA - Okta +2.4% after Q3 beats, upside guidance https://seekingalpha.com/news/3316990-oktaplus-2_4-after-q3-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316990-oktaplus-2_4-after-q3-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316989\" data-ts=\"1512664981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIRS\" target=\"_blank\">PIRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316989-pieris-on-go-early-stage-study-of-inhaled-therapy-for-treatment-resistant-asthma-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pieris on go with early-stage study of inhaled therapy for treatment-resistant asthma; shares ahead 5%</a></h4><ul><li>Pieris Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+4.6%</font>) secures regulatory <a href=\"https://seekingalpha.com/pr/17021092-pieris-pharmaceuticals-announces-ethics-regulatory-clearance-begin-clinical-testing-inhaled\" target=\"_blank\">approvals</a> to launch an Australia-based Phase 1 clinical trial assessing PRS-060/AZD1402 in patients with moderate-to-severe asthma uncontrolled with standard care. The study, in healthy volunteers, is being funded by development partner AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+0.2%</font>).</li><li>PRS-060/AZD1402 is an Anticalin antibody that it is delivered by inhalation which the company says may allow lower doses than alternative therapies while boosting efficacy and tolerability.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3262736-pieris-pharma-plus-41-percent-drug-development-deal-astrazeneca\" target=\"_blank\">Pieris Pharma +41% on drug development deal with AstraZeneca</a> (May 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316989\" data-linked=\"Pieris on go with early-stage study of inhaled therapy for treatment-resistant asthma; shares ahead 5%\" data-tweet=\"$PIRS $PIRS $AZN - Pieris on go with early-stage study of inhaled therapy for treatment-resistant asthma; shares ahead 5% https://seekingalpha.com/news/3316989-pieris-on-go-early-stage-study-of-inhaled-therapy-for-treatment-resistant-asthma-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3316989-pieris-on-go-early-stage-study-of-inhaled-therapy-for-treatment-resistant-asthma-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316987\" data-ts=\"1512664480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIMO\" target=\"_blank\">SIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316987-summit-redstone-upgrades-silicon-motion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Redstone upgrades Silicon Motion</a></h4><ul><li>        Summit Redstone <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171207091536SIMO\" target=\"_blank\">upgrades</a> Silicon Motion (NASDAQ:<a href='https://seekingalpha.com/symbol/SIMO' title='Silicon Motion Technology Corporation'>SIMO</a>) from Hold to Buy.</li><li>               Latest analyst recommendations (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=SIMO:NSQ\" target=\"_blank\">FT</a>): 2 Buy, 9 Outperform, 2 Hold, and 1 Underperform.&nbsp;</li><li>           Median price target: $57.&nbsp; </li><li>                          Silicon Motion shares are&nbsp;<font color='green'>up 1.1%</font>.&nbsp;<br />    &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3316987\" data-linked=\"Summit Redstone upgrades Silicon Motion\" data-tweet=\"$SIMO - Summit Redstone upgrades Silicon Motion https://seekingalpha.com/news/3316987-summit-redstone-upgrades-silicon-motion?source=tweet\" data-url=\"https://seekingalpha.com/news/3316987-summit-redstone-upgrades-silicon-motion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316986\" data-ts=\"1512664065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316986-xoma-licenses-hyperinsulinemia-candidate-xoma-358-to-rezolute-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA licenses hyperinsulinemia candidate XOMA 358 to Rezolute; shares up 10%</a></h4><ul><li>XOMA (<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+10%</font>) has <a href=\"https://seekingalpha.com/pr/17021143-xoma-announces-exclusive-license-agreement-xoma-358-rezolute-inc\" target=\"_blank\">out-licensed</a> product candidate XOMA 358 to Rezolute (ANTB <font color='red'>-15%</font>) for up to $240M.</li><li>Under the terms of the agreement, XOMA will receive milestone payments from Rezolute related to financing, clinical development, regulatory progress and commercial sales and high single-digit to mid-teens royalties. XOMA will also receive $5M in Rezolute common stock and an additional $13M in cash and stock when Rezolute completes certain financing milestones.</li><li>Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities.</li><li>XOMA is entitled to receive low single-digit royalties on net sales of AB101 and other products developed from Rezolute's extended-release and oral plasma kallikrein inhibitor platforms.</li><li>XOMA 358 is a fully human antibody that inhibits the effect of elevated insulin by modulating the insulin receptor. It has Orphan Drug status in the U.S. and Europe for congenital hyperinsulinism.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316986\" data-linked=\"XOMA licenses hyperinsulinemia candidate XOMA 358 to Rezolute; shares up 10%\" data-tweet=\"$XOMA $XOMA $RZLT - XOMA licenses hyperinsulinemia candidate XOMA 358 to Rezolute; shares up 10% https://seekingalpha.com/news/3316986-xoma-licenses-hyperinsulinemia-candidate-xoma-358-to-rezolute-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3316986-xoma-licenses-hyperinsulinemia-candidate-xoma-358-to-rezolute-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316985\" data-ts=\"1512663985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIMHF\" target=\"_blank\">WIMHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316985-william-hill-jumps-on-sector-m-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Hill jumps on sector M&amp;A activity</a></h4><ul> <li>Shares of William Hill (<a href='https://seekingalpha.com/symbol/WIMHF' title='William Hill Plc'>OTCPK:WIMHF</a>, <a href='https://seekingalpha.com/symbol/WIMHY' title='William Hill Plc ADR'>OTCPK:WIMHY</a>) are <font color='green'>up 7.58%</font> in London trading after news broke that GVC is making a play for Ladbrokes.</li> <li>Consolidation in the global betting sector has been widely anticipated.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316895-ladbrokes-plus-29-percent-gvc-holdings-circling\" target=\"_blank\">Ladbrokes +29% with GVC Holdings circling</a> (Dec. 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316985\" data-linked=\"William Hill jumps on sector M&amp;A activity\" data-tweet=\"$WIMHF $WIMHF $WIMHY - William Hill jumps on sector M&amp;A activity https://seekingalpha.com/news/3316985-william-hill-jumps-on-sector-m-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3316985-william-hill-jumps-on-sector-m-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316984\" data-ts=\"1512663686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEF\" target=\"_blank\">GEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316984-greifplus-14-to-52-week-high-after-beating-on-earnings-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greif +14% to 52-week high after beating on earnings, revenue</a></h4><ul>     <li>Greif (<a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a> <font color='green'>+14.1%</font>) spikes to a new 52-week high after posting solid beats for <a href=\"https://seekingalpha.com/news/3316777-greif-beats-0_09-beats-revenue\" target=\"_blank\">FQ4 earnings</a> and revenues despite weather related headwinds.</li>     <li>GEF&nbsp;says Hurricane Harvey adversely affected earnings by $5.3M, higher than initial expectations of a $2.5M adverse weather impact.</li>     <li>Q3 gross profit fell by $1M vs. the year-ago quarter to $182.4M, primarily related to adverse weather events, but operating profit rose by $6.8M to $60.4M and operating profit before special items gained $1.9M to $88.9M; free cash flow jumped $53.9M to $168.2M.</li>     <li>GEF issues in-line guidance for FY 2018, seeing EPS of $3.25-$3.55 vs. $3.40 analyst consensus estimate.</li>     <li>The company notes the end of FY 2017 concludes its three-year Transformation initiative, saying optimization activities identified during the initiative will continue  into 2018 and full-year benefits of 2017 initiatives will be realized in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316984\" data-linked=\"Greif +14% to 52-week high after beating on earnings, revenue\" data-tweet=\"$GEF - Greif +14% to 52-week high after beating on earnings, revenue https://seekingalpha.com/news/3316984-greifplus-14-to-52-week-high-after-beating-on-earnings-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3316984-greifplus-14-to-52-week-high-after-beating-on-earnings-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316981\" data-ts=\"1512662884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTBC\" target=\"_blank\">MTBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316981-medical-transcription-secures-3_9m-capital-raise-shares-off-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medical Transcription secures $3.9M capital raise; shares off 1%</a></h4><ul><li>Medical Transcription Billing (<a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='red'>-1.1%</font>) has <a href=\"https://seekingalpha.com/pr/17021254-mtbc-announces-3_9-million-public-offering-non-convertible-preferred-stock\" target=\"_blank\">sold </a>155,440 shares of its non-convertible 11% Series A Cumulative Redeemable Perpetual Redeemable Preferred Stock at $25 per share yielding gross proceeds of ~$3.9M.</li><li>Net proceeds will be used for general corporate purposes. Closing date is December 11.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316981\" data-linked=\"Medical Transcription secures $3.9M capital raise; shares off 1%\" data-tweet=\"$MTBC - Medical Transcription secures $3.9M capital raise; shares off 1% https://seekingalpha.com/news/3316981-medical-transcription-secures-3_9m-capital-raise-shares-off-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3316981-medical-transcription-secures-3_9m-capital-raise-shares-off-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316957\" data-ts=\"1512662444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316957-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='green'>+72%</font>. <a href='https://seekingalpha.com/symbol/ENTL' title='Entellus Medical'>ENTL</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/ONS-OLD' title='Oncobiologics'>ONS-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316957\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$SAGE $ENTL $VTGN - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3316957-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3316957-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316975\" data-ts=\"1512661162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPL\" target=\"_blank\">LPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316975-lg-display-supply-oled-panels-for-iphone-x\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LG Display could supply OLED panels for iPhone X</a></h4><ul><li>           LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) <a href=\"http://www.theinvestor.co.kr/view.php?ud=20171207000941\" target=\"_blank\">responds</a> to speculation that the company signed an agreement with Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) to supply OLED panels for the iPhone X. </li><li> &ldquo;Regarding the OLED supply deal for Apple&rsquo;s iPhone X, nothing has been set in detail. When anything is confirmed in detail, we will announce it,&rdquo; says LG Display. </li><li> Samsung is currently the only OLED supplier for the iPhone X, which has led to production delays and higher prices. Apple has worked with LG behind the scenes to ramp up its OLED production, but it had looked like LG wouldn&rsquo;t have panels ready until at least 2019. </li><li> Now The Korean Herald suggests LG could ship up to 60M displays in June 2018. </li><li> LG Display shares are&nbsp;<font color='green'>up 0.3%</font>.&nbsp; </li><li> Apple shares are&nbsp;<font color='green'>up 0.60%</font>.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3294093-apple-second-oled-supplier-2019\" target=\"_blank\">Apple won't have second OLED supplier until 2019</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316975\" data-linked=\"LG Display could supply OLED panels for iPhone X\" data-tweet=\"$LPL $LPL $AAPL - LG Display could supply OLED panels for iPhone X https://seekingalpha.com/news/3316975-lg-display-supply-oled-panels-for-iphone-x?source=tweet\" data-url=\"https://seekingalpha.com/news/3316975-lg-display-supply-oled-panels-for-iphone-x\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316974\" data-ts=\"1512661159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAC\" target=\"_blank\">SEAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316974-seachange-vaults-25-after-q3-earnings-top-high-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaChange vaults 25% after Q3 earnings top high estimates</a></h4><ul>   <li>SeaChange International (NASDAQ:<a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a>) is <font color='green'>up 24.8%</font> and already surpassed 10 times normal daily volume after it topped high estimates with its <a href=\"https://seekingalpha.com/news/3316746-seachange-beats-0_08-beats-revenue\" target=\"_blank\">Q3 results</a>.</li>    <li>The company swung to a income from operations of $0.9M on a GAAP basis from a year-ago loss from operations of $8.4M.</li>    <li>Non-GAAP operating income was $0.5M vs. a year-ago loss of $18.7M.</li>     <li>&ldquo;We are very pleased with our progress this past quarter, where growth from existing and new customers for IP video and cloud-based deployments translated into higher revenue and enabled us to achieve non-GAAP operating income,\" said CEO Ed Terino.</li>    <li>Revenue breakout: Products, $11.1M (up 197%); Services, $12.3M (down 24%).</li>    <li>It's expected Q4 revenue of $20M-$24M (vs. consensus for $22.3M) and non-GAAP operating income of $0.02-$0.10/share. For fiscal 2018, it's boosting expectations for revenue to $77M-$81M (vs. $80.3M consensus) and non-GAAP operating income of $0.04-$0.12/share.</li>    <li><a href=\"https://seekingalpha.com/pr/17020441-seachange-international-reports-third-quarter-fiscal-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3316974\" data-linked=\"SeaChange vaults 25% after Q3 earnings top high estimates\" data-tweet=\"$SEAC - SeaChange vaults 25% after Q3 earnings top high estimates https://seekingalpha.com/news/3316974-seachange-vaults-25-after-q3-earnings-top-high-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3316974-seachange-vaults-25-after-q3-earnings-top-high-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316973\" data-ts=\"1512661013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316973-h-and-r-block-gives-back-yesterdays-gains-btig-reiterates-bearish-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;R Block gives back yesterday&#39;s gains; BTIG reiterates bearish outlook</a></h4><ul><li>The company's strong guidance for the rest of fiscal 2018 doesn't jibe with what's becoming an even tougher do-it-yourself tax prep market, says BTIG's Mark Palmer, <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=bahdjk-b\" target=\"_blank\">reiterating his Sell rating</a> and $19 price target.</li><li>Palmer notes H&amp;R Block's (NYSE:<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a>) DIY segment had 3.5% volume growth in fiscal 2017, but that came mostly thanks to a 10% price cut. Now, Intuit (NASDAQ:<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a>) is promising to be aggressive on prices in 2018, and Credit Karma is seeing speedy uptake for its free service.</li><li>After a 10%-plus rise yesterday, shares are&nbsp;<font color='red'>down 8.2%&nbsp;</font>today to $26.61. INTU is&nbsp;<font color='red'>off 0.6%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316828-h-and-r-block-rallies-changing-tax-code\" target=\"_blank\">H&amp;R Block rallies on changing tax code</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316973\" data-linked=\"H&amp;R Block gives back yesterday&#39;s gains; BTIG reiterates bearish outlook\" data-tweet=\"$HRB $HRB $INTU - H&amp;R Block gives back yesterday&#39;s gains; BTIG reiterates bearish outlook https://seekingalpha.com/news/3316973-h-and-r-block-gives-back-yesterdays-gains-btig-reiterates-bearish-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3316973-h-and-r-block-gives-back-yesterdays-gains-btig-reiterates-bearish-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316970\" data-ts=\"1512660610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316970-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+2 Bcf</strong> vs. -7 Bcf consensus, -33 Bcf last week.</li>     <li>Futures&nbsp;<font color='red'>-4.72%</font>&nbsp;to $2.784.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316970\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3316970-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3316970-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316969\" data-ts=\"1512660182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNPS\" target=\"_blank\">SNPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316969-synopsys-initiates-200m-accelerated-share-repurchase-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synopsys initiates $200M accelerated share repurchase program</a></h4><ul><li>        Synopsys (NASDAQ:<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) <a href=\"https://seekingalpha.com/pr/17021222-synopsys-initiates-200-million-accelerated-share-repurchase-agreement\" target=\"_blank\">enters</a> into accelerated share repurchase agreements for $200M of stock.</li><li>                  The agreement was made with JPMorgan Chase Bank, National Association, and MUFG Securities EMEA.    </li><li>               Synopsys will receive an initial share delivery of approximately 1.8M shares and the rest, if any, will be settled no later than May 16 on the repurchase completion.&nbsp;</li><li>Synopsys shares are&nbsp;<font color='green'>up 0.72%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315663-needham-raises-synopsys-price-target\" target=\"_blank\">Needham raises its Synopsys price target</a> (Dec. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316969\" data-linked=\"Synopsys initiates $200M accelerated share repurchase program\" data-tweet=\"$SNPS - Synopsys initiates $200M accelerated share repurchase program https://seekingalpha.com/news/3316969-synopsys-initiates-200m-accelerated-share-repurchase-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3316969-synopsys-initiates-200m-accelerated-share-repurchase-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316966\" data-ts=\"1512659906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316966-lendingclub-outlook-disappoints-shares-tumble-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub outlook disappoints; shares tumble 15%</a></h4><ul><li>The company's investor day isn't going as hoped. Revenue next year is guided to $680M-$705M, with the midpoint of that shy of Street estimates for $699M.</li><li>Q4 revenue is now seen at $155M-$160M vs. previous $158M-$163M, with adjusted EBITDA of $16M-$20M vs. previous $19M-$23M.</li><li>2018 adjusted EBITDA is seen at $75M-$90M - that's up from $42M-$46M expected this year, but at least some Street estimates were for well over $100M.</li><li><a href=\"http://ir.lendingclub.com/Cache/1001230258.PDF?Y=&amp;O=PDF&amp;D=&amp;fid=1001230258&amp;T=&amp;iid=4213397\" target=\"_blank\">Presentation slides</a></li><li><a href=\"https://morganstanley.webcasts.com/starthere.jsp?ei=1172334&amp;tp_key=80dcb0f3a0\" target=\"_blank\">Webcast</a></li><li><a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>&nbsp;<font color='red'>-15.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3316966\" data-linked=\"LendingClub outlook disappoints; shares tumble 15%\" data-tweet=\"$LC - LendingClub outlook disappoints; shares tumble 15% https://seekingalpha.com/news/3316966-lendingclub-outlook-disappoints-shares-tumble-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3316966-lendingclub-outlook-disappoints-shares-tumble-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316960\" data-ts=\"1512659091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316960-apple-suppliers-recover-after-broadcom-sales-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple suppliers recover after Broadcom sales comments</a></h4><ul><li>        Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.5%</font>) suppliers are recovering after Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='green'>+1.8%</font>) <a href=\"https://www.reuters.com/article/us-apple-chip/apple-suppliers-gain-after-broadcom-hint-on-iphone-idUSKBN1E11YR?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FbusinessNews+%28Business+News%29\" target=\"_blank\">suggests</a> the late launch of the iPhone X will boost sales.</li><li>               During the earnings call, Broadcom CEO Hock Tan said the company expects Q1 wireless revenue to grow sequentially as the &ldquo;ramp in demand from our North American customer this year was pushed out compared to prior years.&rdquo; &nbsp;&nbsp;</li><li>               Suppliers on the move: Skyworks (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='red'>-0.5%</font>), Cirrus Logic (<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a> <font color='green'>+1.6%</font>), and Qorvo (<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='red'>-0.5%</font>). &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316681-apple-suppliers-drop-largan-warns-lower-dec-revenue\" target=\"_blank\">Apple suppliers drop after Largan warns of lower Dec. revenue</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316960\" data-linked=\"Apple suppliers recover after Broadcom sales comments\" data-tweet=\"$AAPL $AAPL $AVGO - Apple suppliers recover after Broadcom sales comments https://seekingalpha.com/news/3316960-apple-suppliers-recover-after-broadcom-sales-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3316960-apple-suppliers-recover-after-broadcom-sales-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316959\" data-ts=\"1512659062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316959-centurylinkplus-2_9-after-cramming-probe-finds-mistakes-not-fraud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink +2.9% after cramming probe finds mistakes but not fraud</a></h4><ul>   <li>CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>), <font color='green'>up 2.9%</font> in early going today, says it's <a href=\"https://seekingalpha.com/pr/17021086-centurylink-announces-conclusion-special-committee-investigation\" target=\"_blank\">wrapped an investigation into \"cramming\"</a> that found no evidence of fraud or wrongdoing, but acknowledged failures tied to pricing, promotion and billing that ended up disappointing customers.</li>    <li>A special committee of its independent board members conducted the review after a former employee charged the company with sales misconduct, including charging customers for services they didn't order.</li>    <li>There wasn't evidence to conclude management engaged in wrongdoing, the committee said, and management didn't condone or encourage cramming that wasn't common at the company.</li>    <li>But some products were \"complex and caused confusion, and the resulting bills sometimes failed to meet customer expectations,\" the company says, and software limitations made it difficult to clearly estimate bills for customers.</li>    <li>Also, some customers didn't receive an offered point-of-sale discount due to \"systems and human errors\" and those problems weren't resolved in a timely manner.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316959\" data-linked=\"CenturyLink +2.9% after cramming probe finds mistakes but not fraud\" data-tweet=\"$CTL - CenturyLink +2.9% after cramming probe finds mistakes but not fraud https://seekingalpha.com/news/3316959-centurylinkplus-2_9-after-cramming-probe-finds-mistakes-not-fraud?source=tweet\" data-url=\"https://seekingalpha.com/news/3316959-centurylinkplus-2_9-after-cramming-probe-finds-mistakes-not-fraud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316955\" data-ts=\"1512658443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316955-tsmc-investing-20b-in-3nm-fab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TSMC investing $20B in 3nm fab</a></h4><ul><li>        Taiwan Semiconductor Manufacturing Co. (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) will <a href=\"https://asia.nikkei.com/Business/Companies/TSMC-to-invest-record-20bn-in-advanced-3-nm-chips?page=1\" target=\"_blank\">spend over $20B</a> to build an advanced 3nm chip facility in Taiwan in the early 2020s.</li><li>               The facility will represent TSMC&rsquo;s largest investment and the most advanced 3nm fab in existence.&nbsp;</li><li>                  TSMC has also accelerated production of its first advanced fab in China to 1H18 from 2H18 due to demand.    </li><li>Taiwan Semiconductor shares are&nbsp;<font color='green'>up 0.34%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3314466-taiwan-semi-orders-equipment-applied-materials\" target=\"_blank\">Taiwan Semi orders equipment from Applied Materials</a> (Nov. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315069-samsung-commences-mass-production-power-efficient-10nm-tech\" target=\"_blank\">Samsung commences mass production of power-efficient 10nm tech</a> (Nov. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316955\" data-linked=\"TSMC investing $20B in 3nm fab\" data-tweet=\"$TSM - TSMC investing $20B in 3nm fab https://seekingalpha.com/news/3316955-tsmc-investing-20b-in-3nm-fab?source=tweet\" data-url=\"https://seekingalpha.com/news/3316955-tsmc-investing-20b-in-3nm-fab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316951\" data-ts=\"1512658122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316951-alexion-licenses-halozymes-enhanze-for-up-to-four-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion licenses Halozyme&#39;s ENHANZE for up to four targets</a></h4><ul><li>Alexion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='red'>-1.6%</font>) inks a license and collaboration <a href=\"https://seekingalpha.com/pr/17020808-alexion-halozyme-enter-license-agreement-enhanze-technology\" target=\"_blank\">agreement</a> with Halozyme Therapeutics (<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+1.4%</font>) for the rights to use the latter's ENHANZE drug-delivery technology in up to four candidates, including a next-generation subcutaneous formulation of ALXN1210 which could extend the dosing interval to potentially once per month.</li><li>Under the terms of the agreement, Halozyme will receive $40M upfront, up to $160M for each target developed and mid-single-digit royalties on net sales.</li><li><a href=\"http://www.halozyme.com/technology-and-products/technology/enhanze-technology/default.aspx\" target=\"_blank\">ENHANZE </a>is based on a recombinant human hyaluronidase enzyme that temporarily degrades hyaluronan (a chain of natural sugars in the body) which aids in the dispersion and absorption of injected drugs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316951\" data-linked=\"Alexion licenses Halozyme&#39;s ENHANZE for up to four targets\" data-tweet=\"$ALXN $ALXN $HALO - Alexion licenses Halozyme&#39;s ENHANZE for up to four targets https://seekingalpha.com/news/3316951-alexion-licenses-halozymes-enhanze-for-up-to-four-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3316951-alexion-licenses-halozymes-enhanze-for-up-to-four-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316947\" data-ts=\"1512657502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316947-lululemon-races-higher-on-increased-confidence-for-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon races higher on increased confidence for 2018</a></h4><ul> <li>Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+5.9%</font>) rallies after beating back concerns that sports apparel is off-trend with consumers heading into the holiday season.</li> <li>The strong numbers from Lululemon have a number of investment firms and sector analysts reversing their prior positions and lifting targets.</li> <li>Bank of America Merrill Lynch backs its Buy rating on LULU after the print and lifts its price target to $80.</li> <li>Bloomberg Gadfly's Sarah Halzack points to the company's successful use of local brand ambassadors over expensive celebrity endorsers and tigher brick-and-mortar control than peers. \"It deliberately keeps its wholesale business tiny, confining it mostly to upscale fitness centers. And it has a relatively small store portfolio concentrated in the most productive shopping outlets,\" she observes.</li> <li>Canaccord Genuity upgrades the athletic apparel juggernaut to Hold from Sell after conceding that it overestimated the impact of denim on athleisure.</li> <li>Wells Fargo keeps a Market Peform rating in place after factoring in the \"impressive\" results. The firm is still cautious on valuation and macro variables.</li> <li>Stifel Nicolaus lifts its price target to $75 on optimism over the e-commerce business and gross margin rate into 2018.</li> <li>Needham hikes it price target to $79 from $71 on increased confidence for EPS growth  in 2018.</li> <li>GlobalData Retail analyst Kevin Wathey: \"While other players in the sports and athleisure market struggle, Lululemon continues to go from strength to strength.\"</li> <li>Sources: Reuters, Bloomberg, The Business of Fashion.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316748-lululemon-athletica-beats-0_04-beats-revenue\" target=\"_blank\">Lululemon Athletica beats by $0.04, beats on revenue</a> (Dec. 6)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316759-comparable-sales-shine-lululemon\" target=\"_blank\">Comparable sales shine at Lululemon</a> (Dec. 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316947\" data-linked=\"Lululemon races higher on increased confidence for 2018\" data-tweet=\"$LULU - Lululemon races higher on increased confidence for 2018 https://seekingalpha.com/news/3316947-lululemon-races-higher-on-increased-confidence-for-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3316947-lululemon-races-higher-on-increased-confidence-for-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316946\" data-ts=\"1512657495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLST\" target=\"_blank\">NLST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316946-netlist-confirms-itc-initial-determination-outlines-next-steps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netlist confirms ITC initial determination, outlines next steps</a></h4><ul><li>        Netlist (<a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a>) <a href=\"https://seekingalpha.com/pr/17021075-netlist-comments-patent-infringement-actions-sk-hynix\" target=\"_blank\">confirms</a> more details about the initial determination it received from the U.S. International Trade Commission related to the patent fight with SK Hynix.</li><li>               Administrative Law Judge Bullock determined that Netlist&rsquo;s five patents in question are valid and that the company complied with reasonable and non-discriminatory licensing obligations. &nbsp;&nbsp;</li><li>               But the ALJ found that SK Hynix didn&rsquo;t infringe on those patents, so there was no violation.&nbsp;</li><li>               Both parties are filing additional materials to the Commission, which will then reach a final determination by March 14.&nbsp;</li><li>               Netlist shares are&nbsp;<font color='red'>down 1.8%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315119-netlist-plus-3-percent-itc-opens-investigation-patent-infringement-claims\" target=\"_blank\">Netlist +3% after ITC opens investigation into patent infringement claims</a> (Nov. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316946\" data-linked=\"Netlist confirms ITC initial determination, outlines next steps\" data-tweet=\"$NLST - Netlist confirms ITC initial determination, outlines next steps https://seekingalpha.com/news/3316946-netlist-confirms-itc-initial-determination-outlines-next-steps?source=tweet\" data-url=\"https://seekingalpha.com/news/3316946-netlist-confirms-itc-initial-determination-outlines-next-steps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316940\" data-ts=\"1512656527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316940-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='green'>+71%</font>&nbsp;as SAGE-217 <a href=\"https://seekingalpha.com/news/3316864-sage-therapeutics-sageminus-217-successful-mid-stage-mdd-study-shares-ahead-52-percent\" target=\"_blank\">successful</a> in mid-stage MDD study.</li><li><a href='https://seekingalpha.com/symbol/ENTL' title='Entellus Medical'>ENTL</a> <font color='green'>+50%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3316910-stryker-buy-entellus-medical-662m\" target=\"_blank\">acquired</a> by Stryker.</li><li><a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a> <font color='green'>+29%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316746\" target=\"_blank\">earning</a>.</li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+28%</font>&nbsp;on raising <a href=\"https://seekingalpha.com/news/3316916-digital-power-raises-2018-guidance\" target=\"_blank\">guidance</a>.</li><li><a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+22%</font>&nbsp;on acquiring Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>).</li><li><a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='green'>+13%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316768-tailored-brands-beats-0_18-beats-revenue\" target=\"_blank\">earning</a>.</li><li><a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+8%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316748-lululemon-athletica-beats-0_04-beats-revenue\" target=\"_blank\">earning</a>.</li><li><a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a> <font color='green'>+8%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316836-conns-beats-0_14-beats-revenue\" target=\"_blank\">earning</a>.</li><li><a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17020524-myomo-inc-announces-full-exercise-underwriter-s-allotment-option-follow-public-offering\" target=\"_blank\">full exercise</a> of underwriter's over allotment option in follow-on public offering.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/OSIS' title='OSI Systems, Inc.'>OSIS</a> <font color='green'>+6%</font>&nbsp;as Drexel Hamilton analyst defends the company against yesterday&rsquo;s Muddy Waters report.</li><li><a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a> <font color='green'>+5%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316851-dollar-general-beats-0_04-beats-revenue\" target=\"_blank\">earning</a>.</li><li><a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316940\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SAGE $ENTL $SEAC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3316940-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3316940-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316937\" data-ts=\"1512655901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316937-vale-threatens-to-flood-iron-ore-market-prices-jump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale threatens to flood iron ore market if prices jump</a></h4><ul>     <li>Vale (NYSE:<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>), the world&rsquo;s biggest producer of iron ore, is prepared to <a href=\"https://www.bloomberg.com/news/articles/2017-12-06/vale-to-limit-iron-production-in-value-over-volume-approach\" target=\"_blank\">unleash as much as 50M metric tons of spare capacity</a> to balance the market if prices get too high, CEO Fabio Schvartsman tells Bloomberg.</li><li>High prices would lure inefficient producers back into the market and  risk a repeat of past excesses that led to $1T in value  destruction, the CEO says.</li><li>As Vale shifts focus to high-grade deposits in Brazil&rsquo;s Amazon  region, Schvartsman expects to produce 390M tons in 2018 and cap production at 400M tons over the following four years, well below its 450M-ton capacity.</li><li>VALE <font color='red'>-3.6%</font> premarket.</li><li><a href=\"https://seekingalpha.com/news/3316808-vale-cuts-nickel-production-stays-upbeat-long-term-demand\" target=\"_blank\">Earlier</a>:&nbsp;Vale cuts nickel production but stays upbeat on long-term demand (Dec. 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316937\" data-linked=\"Vale threatens to flood iron ore market if prices jump\" data-tweet=\"$VALE - Vale threatens to flood iron ore market if prices jump https://seekingalpha.com/news/3316937-vale-threatens-to-flood-iron-ore-market-prices-jump?source=tweet\" data-url=\"https://seekingalpha.com/news/3316937-vale-threatens-to-flood-iron-ore-market-prices-jump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316933\" data-ts=\"1512655688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316933-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>&nbsp;<font color='red'>-29%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316878-fibrocell-prices-public-offering-10_5m-shares-31-percent-premarket\" target=\"_blank\">pricing</a> public offering of $10.5M.</li><li><a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a> <font color='red'>-13%</font>.</li><li><a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316931-revance-prices-equity-offering-shares-4-percent-premarket\" target=\"_blank\">pricing</a> equity offering.</li><li><a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316933\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$FCSC $LC $RVNC - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3316933-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3316933-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316931\" data-ts=\"1512655387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVNC\" target=\"_blank\">RVNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316931-revance-prices-equity-offering-shares-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revance prices equity offering, shares down 4% premarket</a></h4><ul><li>Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) slips&nbsp;<font color='red'>4%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17021080-revance-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~5.3M shares of common stock at $31 per share. The offering includes 500K shares from existing investors.</li><li>Underwriters over-allotment is an additional ~800K shares. Closing date is December 11.</li><li>Yesterday's close was $33.65.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316931\" data-linked=\"Revance prices equity offering, shares down 4% premarket\" data-tweet=\"$RVNC - Revance prices equity offering, shares down 4% premarket https://seekingalpha.com/news/3316931-revance-prices-equity-offering-shares-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316931-revance-prices-equity-offering-shares-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316926\" data-ts=\"1512655271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHAK\" target=\"_blank\">SHAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316926-morgan-stanley-pulls-bearish-view-on-shake-shack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley pulls bearish view on Shake Shack</a></h4><ul> <li>Morgan Stanley upgrades Shake Shack (NYSE:<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a>) after noting the strong performance for new stores in key markets.</li> <li>Analyst John Glass now sees a more balance risk-reward profile on the restaurant stock due to the sales momentum.</li> <li>Shares of Shake Shack are now rated at Equal-weight (from Underweight) and assigned a price target of $41 (from $34).</li><li>Sources: CNBC and Morningstar</li> <li>SHAK <font color='green'>+1.15%</font> premarket to $42.26.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316926\" data-linked=\"Morgan Stanley pulls bearish view on Shake Shack\" data-tweet=\"$SHAK - Morgan Stanley pulls bearish view on Shake Shack https://seekingalpha.com/news/3316926-morgan-stanley-pulls-bearish-view-on-shake-shack?source=tweet\" data-url=\"https://seekingalpha.com/news/3316926-morgan-stanley-pulls-bearish-view-on-shake-shack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316918\" data-ts=\"1512654764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316918-post-earnings-rally-for-tailored-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings rally for Tailored Brands</a></h4><ul> <li>Shares of Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>) rip an early gain after the retailer blasted past <a href=\"https://seekingalpha.com/pr/17020506-tailored-brands-inc-reports-fiscal-2017-third-quarter-results\" target=\"_blank\">Q3</a> estimates.</li> <li>Comparable sales by brand: Men's Warehouse -1.0%, Jos. A. Bank +4.9%, K&amp;G -0.6%, Moores -2.6%.</li> <li>Retail gross margin was flat compared to a year ago despite the drop in total sales.</li> <li>Standing out even more than the Q3 numbers was the strong profit guidance from Tailored Brands. Full-year EPS of $2.03 to $2.08 is expected vs. $1.88 consensus estimate.</li>   <li>Shares of Tailored Brands are <font color='green'>up 14.49%</font> in premarket action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316918\" data-linked=\"Post-earnings rally for Tailored Brands\" data-tweet=\"$TLRD - Post-earnings rally for Tailored Brands https://seekingalpha.com/news/3316918-post-earnings-rally-for-tailored-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3316918-post-earnings-rally-for-tailored-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316916\" data-ts=\"1512654721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316916-digital-power-raises-2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Power raises 2018 guidance</a></h4><ul><li>        Digital Power (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <a href=\"https://seekingalpha.com/pr/17020755-digital-power-corporation-raises-2018-revenue-guidance-50-percent-prior-estimate\" target=\"_blank\">raises</a> its 2018 guidance with revenue up from $25M to between $36M and $38M.</li><li>               The company reaffirms its December quarter guidance with revenue from $4.2M to $4.9M.&nbsp;</li><li>               Digital Power shares are&nbsp;<font color='green'>up 35%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316804-digital-power-denies-rumors-amazon-cryptocurrency-deal\" target=\"_blank\">Digital Power denies rumors of Amazon cryptocurrency deal</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316916\" data-linked=\"Digital Power raises 2018 guidance\" data-tweet=\"$DPW - Digital Power raises 2018 guidance https://seekingalpha.com/news/3316916-digital-power-raises-2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316916-digital-power-raises-2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316915\" data-ts=\"1512654351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316915-squares-bitcoin-service-impresses-jefferies-shares-up-1_8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square&#39;s Bitcoin service impresses Jefferies; shares up 1.8% premarket</a></h4><ul><li>via Bloomberg</li><li>After meeting with Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) CFO Sarah Friar, and impressed with how easy the Bitcoin service is to use, Jefferies' Ramsey El-Assal is \"incrementally positive about the potential consumer appeal.\"</li><li>The platform could see big uptake should Square decide to roll it out to all customers, he says, continuing to rate the stock a Buy.</li><li>Shares&nbsp;<font color='green'>up 1.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3316915\" data-linked=\"Square&#39;s Bitcoin service impresses Jefferies; shares up 1.8% premarket\" data-tweet=\"$SQ - Square&#39;s Bitcoin service impresses Jefferies; shares up 1.8% premarket https://seekingalpha.com/news/3316915-squares-bitcoin-service-impresses-jefferies-shares-up-1_8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316915-squares-bitcoin-service-impresses-jefferies-shares-up-1_8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316913\" data-ts=\"1512654210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRNS\" target=\"_blank\">MRNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316913-sages-up-move-carries-marinus-up-31-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SAGE&#39;s up move carries Marinus, up 31% premarket</a></h4><ul><li>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a>) is up&nbsp;<font color='green'>31%</font>&nbsp;premarket on robust volume as it rides the wave of buying in Sage Therapeutics after it reported successful Phase 2 results for MDD med SAGE-217, a GABA modulator.</li><li>Marinus is developing its own GABA modulator, ganaxolone, for postpartum depression and a rare seizure disorder.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316864-sage-therapeutics-sageminus-217-successful-mid-stage-mdd-study-shares-ahead-52-percent\" target=\"_blank\">Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316913\" data-linked=\"SAGE&#39;s up move carries Marinus, up 31% premarket\" data-tweet=\"$MRNS - SAGE&#39;s up move carries Marinus, up 31% premarket https://seekingalpha.com/news/3316913-sages-up-move-carries-marinus-up-31-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316913-sages-up-move-carries-marinus-up-31-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316912\" data-ts=\"1512654202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMES\" target=\"_blank\">EMES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316912-emerge-energyminus-1_8-after-filing-for-100m-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerge Energy -1.8% after filing for $100M offering</a></h4><ul>     <li>Emerge Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a>) <font color='red'>-1.8%</font> premarket after <a href=\"http://archive.fast-edgar.com//20171206/AUZPQ22CZ222EJZZ26222ZZZQSDFZDQ7Z292/\" target=\"_blank\">filing</a> for an offering of $100M common units and ~9.84M units by selling unitholders.</li><li>Separately, B. Riley FBR initiates coverage of EMES with a <a href=\"https://www.streetinsider.com/Analyst+Comments/B.RileyFBR+Starts+Emerge+Energy+Services+LP+%28EMES%29+at+Neutral/13576994.html\" target=\"_blank\">Neutral rating</a> and a $9 price target.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316912\" data-linked=\"Emerge Energy -1.8% after filing for $100M offering\" data-tweet=\"$EMES - Emerge Energy -1.8% after filing for $100M offering https://seekingalpha.com/news/3316912-emerge-energyminus-1_8-after-filing-for-100m-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316912-emerge-energyminus-1_8-after-filing-for-100m-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316910\" data-ts=\"1512653664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYK\" target=\"_blank\">SYK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316910-stryker-to-buy-entellus-medical-for-662m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stryker to buy Entellus Medical for $662M</a></h4><ul><li>Stryker (NYSE:<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a>) has agreed to <a href=\"https://seekingalpha.com/pr/17021063-entellus-medical-announces-definitive-agreement-acquired-stryker-corporation-purchase-price\" target=\"_blank\">acquire </a>Entellus Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTL' title='Entellus Medical'>ENTL</a>) for $24 per share in cash representing a transaction value of ~$662M.</li><li><a href=\"https://www.entellusmedical.com/\" target=\"_blank\">Entellus </a>develops products used in ENT procedures.</li><li>ENTL will resume trading at 8:45 am ET. Yesterday's close was $16.01.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316910\" data-linked=\"Stryker to buy Entellus Medical for $662M\" data-tweet=\"$SYK $SYK $ENTL - Stryker to buy Entellus Medical for $662M https://seekingalpha.com/news/3316910-stryker-to-buy-entellus-medical-for-662m?source=tweet\" data-url=\"https://seekingalpha.com/news/3316910-stryker-to-buy-entellus-medical-for-662m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316906\" data-ts=\"1512653358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSIS\" target=\"_blank\">OSIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316906-drexel-hamilton-analyst-defends-osi-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drexel Hamilton analyst defends OSI Systems</a></h4><ul><li>        OSI Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSIS' title='OSI Systems, Inc.'>OSIS</a>) share are&nbsp;<font color='green'>up 6.7%</font>&nbsp;premarket after a Drexel Hamilton analyst defends the company against yesterday&rsquo;s Muddy Waters report.</li><li>               Analyst Brian Ruttenbur, who has followed OSI Systems for 15 years, estimates that the key Mexico contract contributes $120M to annual revenues with profits close to $30M of EBITDA. Muddy Waters had estimated $100M of EBITDA. Ruttenbur also expects the contract to renew next year with a lower revenue run rate that&rsquo;s already factored into his estimates.&nbsp;</li><li>               OSI Systems shares closed yesterday down 29.2% after the Muddy Waters report.&nbsp;</li><li>               Source: <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316662-osi-systems-minus-11_8-percent-muddy-waters-report\" target=\"_blank\">OSI Systems -11.8% after Muddy Waters report</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316906\" data-linked=\"Drexel Hamilton analyst defends OSI Systems\" data-tweet=\"$OSIS - Drexel Hamilton analyst defends OSI Systems https://seekingalpha.com/news/3316906-drexel-hamilton-analyst-defends-osi-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3316906-drexel-hamilton-analyst-defends-osi-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316904\" data-ts=\"1512653316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMKTA\" target=\"_blank\">IMKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316904-ingles-markets-jumps-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ingles Markets jumps after earnings</a></h4><ul> <li>Shares of Ingles Markets (NASDAQ:<a href='https://seekingalpha.com/symbol/IMKTA' title='Ingles Markets, Incorporated'>IMKTA</a>) are higher in premarket trading after the supermarket operator tops earnings estimates.</li> <li>Comparable sales were up 3.6% during the period as hurricane activity added to demand during the quarter.</li> <li>Gross profit came in at 24.0% of sales. Operating and administrative expenses fell 110 bps to 20.2% of sales.</li> <li>IMKTA <font color='green'>+2.51%</font> premarket to $28.39 vs. a 52-week trading range of $20.75 to $52.40.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316872-ingles-markets-reports-q4-results\" target=\"_blank\">Ingles Markets reports Q4 results</a> (Dec. 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316904\" data-linked=\"Ingles Markets jumps after earnings\" data-tweet=\"$IMKTA - Ingles Markets jumps after earnings https://seekingalpha.com/news/3316904-ingles-markets-jumps-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3316904-ingles-markets-jumps-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316901\" data-ts=\"1512653237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVM\" target=\"_blank\">CVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316901-cel-sci-reports-recent-data-review-idmc-for-pivotal-phase-3-head-and-neck-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study</a></h4><ul> <li>CEL-SCI Corporation (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a>) <a href=\"https://seekingalpha.com/pr/17020925-cel-sci-reports-recent-data-review-independent-data-monitoring-committee-pivotal-phase-3-head\" target=\"_blank\">announces</a> that the Independent Data Monitoring Committee &#40;IDMC&#41;&nbsp;has completed its review for the Company&rsquo;s       pivotal Phase 3 head and neck cancer study of its investigational       immunotherapy Multikine (Leukocyte Interleukin, Injection). The study enrolled 928 patients.</li>     <li>The IDMC saw no evidence of any significant safety questions and recommended continuing the study.</li>                    <li>Multikine (Leukocyte Interleukin, Injection) is the trademark that       CEL-SCI has registered for this investigational therapy, and this       proprietary name is subject to FDA review in connection with the       Company's future anticipated regulatory submission for approval.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket on modest volume.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3316901\" data-linked=\"CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study\" data-tweet=\"$CVM - CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study https://seekingalpha.com/news/3316901-cel-sci-reports-recent-data-review-idmc-for-pivotal-phase-3-head-and-neck-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3316901-cel-sci-reports-recent-data-review-idmc-for-pivotal-phase-3-head-and-neck-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316898\" data-ts=\"1512652740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316898-mellanox-technologies-releases-fy18-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox Technologies releases FY18 guidance</a></h4><ul><li>        Mellanox Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <a href=\"https://seekingalpha.com/filing/3790958\" target=\"_blank\">releases slides</a> showing FY18 revenue growth guidance in the low to mid-teens on the year to $967.6M.</li><li>                  The company sees gross margins up 68% to 69% and operating income growth at 50%.    </li><li>               Mellanox shares are&nbsp;<font color='green'>up 1.1%&nbsp;</font>premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316726-mellanox-tech-plus-2_1-percent-bank-talks-rumor\" target=\"_blank\">Mellanox Tech +2.1% on bank talks rumor</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316898\" data-linked=\"Mellanox Technologies releases FY18 guidance\" data-tweet=\"$MLNX - Mellanox Technologies releases FY18 guidance https://seekingalpha.com/news/3316898-mellanox-technologies-releases-fy18-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316898-mellanox-technologies-releases-fy18-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316897\" data-ts=\"1512652682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316897-jinkosolarminus-4-after-q3-earnings-solar-module-shipmentsminus-17-vs-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JinkoSolar -4% after Q3 earnings; solar module shipments -17% vs. Q2</a></h4><ul>     <li>JinkoSolar (NYSE:<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a>) <font color='red'>-4.2%</font> premarket despite posting better than expected <a href=\"https://seekingalpha.com/news/3316838-jinkosolar-holding-beats-0_02-beats-revenue\" target=\"_blank\">Q3 earnings</a> and revenues, as solar module shipments of 2.374 GW fell 17.7% Q/Q - exceeding the company's guidance of 2.1-2.3 GW - while rising 47.8% Y/Y from 1.606 GW in the year-ago quarter.</li>     <li>JKS says Q3 revenue of $965M was 12.8% higher than a year ago but 19% lower than in Q2 when revenue reached $1.17B.</li>     <li>Q3 gross margin was 12%, compared with 10.5% in Q2 and 19.2% in Q3 2016.</li>     <li>For Q4, JKS estimates total solar module shipments of 2.3-2.5 GW; for the full year, it sees shipments of 9.6-9.8 GW, up from the previous quarter guidance of 8.5-9.0 GW.</li>     <li>JKS says \"demand in China remained strong during the quarter as the distributed generation market there grows rapidly.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316897\" data-linked=\"JinkoSolar -4% after Q3 earnings; solar module shipments -17% vs. Q2\" data-tweet=\"$JKS - JinkoSolar -4% after Q3 earnings; solar module shipments -17% vs. Q2 https://seekingalpha.com/news/3316897-jinkosolarminus-4-after-q3-earnings-solar-module-shipmentsminus-17-vs-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3316897-jinkosolarminus-4-after-q3-earnings-solar-module-shipmentsminus-17-vs-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316896\" data-ts=\"1512652405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENTL\" target=\"_blank\">ENTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316896-entellus-medical-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entellus Medical trading halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading</a> in Entellus Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTL' title='Entellus Medical'>ENTL</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316896\" data-linked=\"Entellus Medical trading halted pending news\" data-tweet=\"$ENTL - Entellus Medical trading halted pending news https://seekingalpha.com/news/3316896-entellus-medical-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3316896-entellus-medical-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316892\" data-ts=\"1512652276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316892-acorda-refiles-u-s-marketing-application-for-parkinsons-med-inbrija-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acorda refiles U.S. marketing application for Parkinson&#39;s med Inbrija; shares up 5% premarket</a></h4><ul><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket, albeit on only 50 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17020769-acorda-resubmits-new-drug-application-inbrija-cvtminus-301-levodopa-inhalation-powder\" target=\"_blank\">announcement </a>that it has resubmitted its NDA to the FDA seeking approval for INBRIJA (formerly CVT-301) for the treatment of OFF periods in Parkinson's disease patients receiving a carbidopa/levodopa regimen.</li><li>The company says the updated filing addresses the two issues cited in the Refusal to File letter: the date that the manufacturing site would be ready for inspection and a question related to the submission of the drug master production record.</li><li>The application is being filed under the 505(b)(2) pathway which allows the inclusion of data generated by third parties.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292304-fda-rejects-acordas-marketing-application-parkinsons-candidate-inbrija-shares-24-percent\" target=\"_blank\">FDA rejects Acorda's marketing application for Parkinson's candidate Inbrija; shares down 24% premarket</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316892\" data-linked=\"Acorda refiles U.S. marketing application for Parkinson&#39;s med Inbrija; shares up 5% premarket\" data-tweet=\"$ACOR - Acorda refiles U.S. marketing application for Parkinson&#39;s med Inbrija; shares up 5% premarket https://seekingalpha.com/news/3316892-acorda-refiles-u-s-marketing-application-for-parkinsons-med-inbrija-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316892-acorda-refiles-u-s-marketing-application-for-parkinsons-med-inbrija-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316895\" data-ts=\"1512652231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMVHF\" target=\"_blank\">GMVHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316895-ladbrokesplus-29-gvc-holdings-circling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ladbrokes +29% with GVC Holdings circling</a></h4><ul> <li>GVC Holdings (<a href='https://seekingalpha.com/symbol/GMVHF' title='GVC Holdings Plc'>OTCPK:GMVHF</a>) confirms that it is in advanced talks to acquire betting firm Ladbrokes Coral Group (<a href='https://seekingalpha.com/symbol/LDBKF' title='Ladbrokes Coral Group Plc'>OTCPK:LDBKF</a>, <a href='https://seekingalpha.com/symbol/LDCOY' title='Ladbrokes Coral Group Plc ADR'>OTCPK:LDCOY</a>).</li> <li>The deal price for Ladbrokers could go as high as &pound;3.9B ($5.2B), according to reports from the U.K.</li> <li>A successful bid by GVC for Ladbrokes could <a href=\"https://www.reuters.com/article/us-ladbrokes-m-a-gvc-holdings/gvc-raises-uk-gambling-stakes-with-5-2-billion-ladbrokes-bid-idUSKBN1E10Q8\" target=\"_blank\">push</a> the combined company into the FTSE 100 Index, according to Reuters.</li> <li>Shares of Ladbrokes are <font color='green'>up 29%</font> in London trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316895\" data-linked=\"Ladbrokes +29% with GVC Holdings circling\" data-tweet=\"$GMVHF $GMVHF $LDBKF - Ladbrokes +29% with GVC Holdings circling https://seekingalpha.com/news/3316895-ladbrokesplus-29-gvc-holdings-circling?source=tweet\" data-url=\"https://seekingalpha.com/news/3316895-ladbrokesplus-29-gvc-holdings-circling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316894\" data-ts=\"1512652077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316894-cienaplus-5_8-after-mixed-q4-results-share-repurchase-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ciena +5.8% after mixed Q4 results, share repurchase program</a></h4><ul><li>        Ciena (NASDAQ:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) shares are<font color='green'>&nbsp;up 5.8%</font>&nbsp;premarket after Q4 results that beat revenue estimates but missed on EPS. In long-term guidance, Ciena sees net revenue increasing 5% to 7% over the next three years with EPS rising 14% to 16%.</li><li>               Segment revenue: Total Networking Platforms, $598.9M (+6%); Total Software and Software-Related Services, $41.8M (+11%); Total Global Services, $103.7M (-8%).&nbsp;</li><li>               Key metrics: Adjusted gross margin, 44.2% (-1% Y/Y); adjusted operating margin, 11.9% (-0.9%); cash and investments, $969.4M; cash flow from operations, $138.5M; average days sales outstanding, 75; accounts receivable balance, $622.2M; inventories, $267.1M.&nbsp;</li><li>               Share repurchase: Ciena&rsquo;s board approves share repurchase program of up to $300M of common stock through the end of FY20.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17020848-ciena-reports-fiscal-fourth-quarter-2017-year-end-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316859-ciena-misses-0_04-beats-revenue\" target=\"_blank\">Ciena misses by $0.04, beats on revenue</a> (Dec. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316894\" data-linked=\"Ciena +5.8% after mixed Q4 results, share repurchase program\" data-tweet=\"$CIEN - Ciena +5.8% after mixed Q4 results, share repurchase program https://seekingalpha.com/news/3316894-cienaplus-5_8-after-mixed-q4-results-share-repurchase-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3316894-cienaplus-5_8-after-mixed-q4-results-share-repurchase-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316878\" data-ts=\"1512650812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCSC\" target=\"_blank\">FCSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316878-fibrocell-prices-public-offering-of-10_5m-shares-down-31-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrocell prices public offering of $10.5M; shares down 31% premarket</a></h4><ul> <li>Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <a href=\"https://seekingalpha.com/pr/17020882-fibrocell-announces-pricing-10_5-million-underwritten-public-offering\" target=\"_blank\">prices</a> a public offering of 13.6M shares of its common stock and common warrants at a combined price of $0.77.</li>     <li>The common warrants will expire five years from the date of issuance. The Common Stock and the accompanying warrants can only be purchased together but will be issued separately.</li>  <li>Underwriters are granted a 30-day option to purchase up to 2M shares at a purchase price of $0.76 per share and/or common warrants.</li>  <li>The expected gross proceeds are ~$10.5M. Net proceeds will be used for the continued clinical and pre-clinical development of its product candidates, FCX-007 and FCX-013, for the research and other general corporate purposes.</li>  <li>Closing date is December 11.</li><li>Shares are down&nbsp;<font color='red'>31%</font>&nbsp;premarket on robust volume. Yesterday's close was $1.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316878\" data-linked=\"Fibrocell prices public offering of $10.5M; shares down 31% premarket\" data-tweet=\"$FCSC - Fibrocell prices public offering of $10.5M; shares down 31% premarket https://seekingalpha.com/news/3316878-fibrocell-prices-public-offering-of-10_5m-shares-down-31-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316878-fibrocell-prices-public-offering-of-10_5m-shares-down-31-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316877\" data-ts=\"1512650520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316877-piper-jaffray-downgrades-yelp-lowers-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray downgrades Yelp, lowers price target</a></h4><ul><li>        Piper Jaffray downgrades Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) to Underweight and lowers the price target by a dollar to $37.</li><li>               Analyst Sam Kemp expects Yelp management to &ldquo;guide down&rdquo; 2018 revenue estimates after lowering the Q4 guidance by about 2% because of the &ldquo;messiness of removing Eat24.&rdquo;&nbsp;</li><li>               Kemp sees Facebook and Google making it difficult for Yelp to grow traffic and user numbers.&nbsp;</li><li>                  Source: Bloomberg First Word    </li><li>               Yelp shares are&nbsp;<font color='red'>down 4.5%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3316877\" data-linked=\"Piper Jaffray downgrades Yelp, lowers price target\" data-tweet=\"$YELP - Piper Jaffray downgrades Yelp, lowers price target https://seekingalpha.com/news/3316877-piper-jaffray-downgrades-yelp-lowers-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3316877-piper-jaffray-downgrades-yelp-lowers-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316869\" data-ts=\"1512649433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VKTX\" target=\"_blank\">VKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316869-viking-therapeutics-prices-equity-offering-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viking Therapeutics prices equity offering; shares down 8% premarket</a></h4><ul><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a>) slips&nbsp;<font color='red'>8%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17020653-viking-therapeutics-announces-pricing-12_8-million-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~5.1M shares of common stock at $2.50 per share. Underwriters over-allotment is an additional ~770K shares. Closing date is December 11.</li><li>Net proceeds will fund the continued development of VK5211, VK2809 and VK0214, R&amp;D, working capital and general corporate purposes.</li><li>Yesterday's close was $2.99.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316869\" data-linked=\"Viking Therapeutics prices equity offering; shares down 8% premarket\" data-tweet=\"$VKTX - Viking Therapeutics prices equity offering; shares down 8% premarket https://seekingalpha.com/news/3316869-viking-therapeutics-prices-equity-offering-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316869-viking-therapeutics-prices-equity-offering-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316864\" data-ts=\"1512649124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316864-sage-therapeutics-sageminus-217-successful-in-mid-stage-mdd-study-shares-ahead-52-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics&#39; SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket</a></h4><ul><li>Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) is up&nbsp;<font color='green'>52%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17020765-sage-therapeutics-reports-positive-top-line-results-phase-2-placebo-controlled-trial\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder &#40;MDD&#41;, a Fast Track indication in the U.S.</li><li>The 89-subject study met its primary endpoint of a statistically significant average reduction in HAM-D score from baseline to day 15 (p&lt;0.0001) versus placebo. HAM-D is a rating scale for depression. At day 15, 64% of patients in the treatment group achieved remission compared to 23% for placebo (p=0.0005). Other secondary endpoints were also met.</li><li>SAGE-217 was generally well-tolerated with no serious or severe adverse events observed. The most common adverse events were headache, dizziness, nausea and drowsiness.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li><li><a href=\"http://www.sagerx.com/programs.php#217\" target=\"_blank\">SAGE-217</a>, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system &#40;CNS&#41;, plays a key role in regulating CNS function. The company intends to advance the program into Phase 3 development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316864\" data-linked=\"Sage Therapeutics&#39; SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket\" data-tweet=\"$SAGE - Sage Therapeutics&#39; SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket https://seekingalpha.com/news/3316864-sage-therapeutics-sageminus-217-successful-in-mid-stage-mdd-study-shares-ahead-52-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316864-sage-therapeutics-sageminus-217-successful-in-mid-stage-mdd-study-shares-ahead-52-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316862\" data-ts=\"1512649017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEST\" target=\"_blank\">DEST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316862-on-destination-maternitys-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Destination Maternity&#39;s Q3</a></h4><ul><li>Destination Maternity (NASDAQ:<a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a>) reports comparable sales rose 1.1% in <a href=\"https://seekingalpha.com/pr/17020823-destination-maternity-reports-third-quarter-first-nine-months-fiscal-2017-results\" target=\"_blank\">Q3</a>.</li><li>Gross margin rate down 10 bps to 52.8%.</li><li>SG&amp;A expense rate grew 200 bps to 55.2%.</li><li>Inventory -0.5% to $73.94M.</li><li>Total retail location count -82 Y/Y to 1,147.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316862\" data-linked=\"More on Destination Maternity&#39;s Q3\" data-tweet=\"$DEST - More on Destination Maternity&#39;s Q3 https://seekingalpha.com/news/3316862-on-destination-maternitys-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3316862-on-destination-maternitys-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316843\" data-ts=\"1512646390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CONN\" target=\"_blank\">CONN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316843-on-conns-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Conn&#39;s Q3</a></h4><ul>     <li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) reports retail same-store sales fell 7% in <a href=\"https://seekingalpha.com/pr/17020780-conns-inc-reports-third-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Q3</a>.</li>     <li>Net sales by category:&nbsp;Furniture and mattress: $97.15M (-1.8%);&nbsp;Home appliance: $83.84M (-2.3%);&nbsp;Consumer electronics: $58.06M (-11.6%); Home office: $20.3M (-10.8%); Other: $4.45M (-10.3%);&nbsp;Repair service agreement commissions: $24.49M (-7.1%);&nbsp;Service revenues: $3.53M (-2.5%).</li>     <li>Credit revenue advanced 18.8% to $81.3M.</li>     <li>Furniture unit volume decreased 12.5% &amp; mattress unit volume -15.1%.</li>     <li>Home appliance unit volume slipped 5%.</li>     <li>Consumer electronic&nbsp;unit volume dropped 11.9%.</li>     <li>Home office unit volume squeezed 20.4%.</li>     <li>Retail gross margin improved 230 bps to 39.8%.</li>     <li>Operating margin down 90 bps to 10.1%.</li>     <li>Retail store count +3 Y/Y to 116.</li>     <li><b>Q4 Guidance</b>: Same-store sales: down mid single digits; Retail gross margin: 39% to 39.5%; SG&amp;A expense rate: 27% to 29%; Provision for bad debts: $55M to $59.5M; Finance charges and other revenues: $86M to $90M; Interest expense : $19M to $20.5M.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3316843\" data-linked=\"More on Conn&#39;s Q3\" data-tweet=\"$CONN - More on Conn&#39;s Q3 https://seekingalpha.com/news/3316843-on-conns-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3316843-on-conns-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}